Block & Leviton is investigating aTyr Pharma after the company announced that its Phase 3 trial for efzofitimod, an experimental therapy for pulmonary sarcoidosis, failed to meet the study’s primary endpoint. aTyr Pharma’s stock price plummeted over 80% on September 15 following the announcement.
Contact our attorneys for a no-cost case evaluation.